CICC: Maintains "outperform" rating on Hysan Bio (01548.HK), raises target price to HKD 21.50.

According to the app of Wisdom Finance, issued a research report stating that it maintains the profit forecast for Kingsway Group Holdings Limited (01548.HK) for 2025 and 2026, and also maintains an outperform rating for the industry. However, due to the recent upward shift in the valuation center of the pharmaceutical sector, the target price has been raised by 22.2% to 21.50 Hong Kong dollars (based on the DCF valuation method), providing a potential upside of 21.3% compared to the current stock price.